Kala Pharmaceuticals (KALA) Tops Q2 EPS by 6c

Kala Pharmaceuticals (NASDAQ: KALA) reported Q2 EPS of ($0.38), $0.06 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $2.02 million.

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ennis (EBF) Reports In-Line Q1 EPS
• Hermès can regain momentum despite China weakness, Jefferies says